Mizuho Securities Remains Neutral on Myriad Genetics (MYGN); Awaiting Reimbursement Progress
Mizuho Securities reiterated a Neutral rating and $42.00 price target on Myriad Genetics (NASDAQ: MYGN) following the company's 2Q earnings ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
